Python Molecule Offers New Hope in Obesity Treatment

Scientists have identified a molecule in pythons, called pTOS, that may contribute to their remarkable ability to consume massive meals and then fast for extended periods. This molecule has shown significant potential for the development of new obesity drugs.

When this python metabolite, which spikes in their blood after eating, was administered to obese mice, the mice reduced their food intake and experienced rapid weight loss.

The Secrets of Python Metabolism

Burmese pythons are known for their extraordinary metabolic capabilities, able to consume prey weighing up to 100% of their own body weight. Following a meal, their heart expands by 25%, and their metabolism can accelerate by a staggering 4,000-fold to facilitate the intense digestion process. Remarkably, they can then fast for 12 to 18 months without suffering apparent negative health effects.

The Discovery of pTOS

Researchers initially focused on metabolites involved in the pythons' post-feeding heart growth. They meticulously analyzed blood samples from young Burmese pythons both before and after consuming a meal equivalent to about 25% of their body weight. Out of more than 200 molecules that showed significant increases, pTOS stood out, increasing over 1,000-fold in concentration.

It has been found that pTOS is produced by the snake’s gut bacteria. Interestingly, it is also present at low levels in human urine.

Promising Effects in Mice

When pTOS was administered to laboratory mice, it did not significantly impact their energy expenditure or the size of their organs. However, its effect on appetite and feeding behaviors was notable.

Obese mice treated with pTOS consumed less food than control mice and subsequently lost 9% of their body weight over a 28-day period.

Unique Mechanism and Therapeutic Potential

Unlike existing GLP-1 medications, such as Wegovy, which primarily slow stomach-emptying and can lead to side effects like nausea, pTOS appears to act on the hypothalamus. This brain region is well-known for its crucial role in regulating appetite.

Researchers suggest that pTOS could function as a novel appetite suppressant, potentially without the typical side effects associated with some current obesity drugs. Further research is essential before clinical application. As pTOS occurs naturally in humans, it is expected to be safe for development.

Published Findings

The groundbreaking findings were officially published in the esteemed journal Nature Metabolism.